{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:04:34Z","timestamp":1776830674434,"version":"3.51.2"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T00:00:00Z","timestamp":1652659200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Botulism antitoxin heptavalent (A, B, C, D, E, F, and G \u2013 Equine; BAT) product is a sterile solution of F(ab')<jats:sub>2<\/jats:sub> and F(ab')<jats:sub>2<\/jats:sub>\u2010related antibody fragments prepared from plasma obtained from horses that have been immunized with a specific serotype of botulinum toxoid and toxin. BAT product is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A to G in adults and pediatric patients. Pharmacokinetic and exposure\u2010response models were used to explore the relationship between BAT product exposure and the probability of survival, and the occurrence of relevant moderate clinical signs observed during the preclinical development of BAT product to justify the clinical dose. The predicted probability of survival in humans for all serotypes of botulinum neurotoxin was more than 95.9% following intravenous administration of one vial of BAT product. Furthermore, this BAT product dose is expected to result in significant protection against clinical signs in human adults for all botulinum neurotoxin serotypes. Our exposure response model indicates that we have sufficient antitoxin levels to give full protection at various theoretical exposure levels and, based on neutralization capacity\/potency of one dose of BAT product, it is expected to exceed the amount of circulating botulinum neurotoxin.<\/jats:p>","DOI":"10.1002\/cpt.2620","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T12:09:49Z","timestamp":1650888589000},"page":"171-180","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Exposure\u2010Response Modeling and Simulation to Support Human Dosing of Botulism Antitoxin Heptavalent Product"],"prefix":"10.1111","volume":"112","author":[{"given":"Martin","family":"Beliveau","sequence":"first","affiliation":[{"name":"Certara Strategic Consulting Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Anderson","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc. Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Barker","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc. Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shantha","family":"Kodihalli","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc. Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Simard","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Hall","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc. Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason S.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions Inc. Winnipeg Manitoba Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,5,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.8.1059"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1152"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-85173-5_3"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14130"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.08.002"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.051908.125345"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a121239"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-129-3-199808010-00011"},{"key":"e_1_2_10_10_1","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E","volume":"59","author":"Centers for Disease Control and Prevention (CDC)","year":"2010","journal-title":"MMWR Morb. Mortal. Wkly. Rep"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051926"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000069073"},{"key":"e_1_2_10_13_1","first-page":"293","article-title":"Type E botulism: its epidemiology, prevention and specific treatment","volume":"54","author":"Dolman C.E.","year":"1963","journal-title":"Can. J. Public Heal. Rev. Can. Sant\u00e9 Publique"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/508176"},{"key":"e_1_2_10_15_1","first-page":"251","article-title":"Wound botulism in injection drug users: time to antitoxin correlates with intensive care unit length of stay","volume":"10","author":"Offerman S.R.","year":"2009","journal-title":"West. J. Emerg. Med."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90988-4"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz515"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14010019"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0209019"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186892"},{"key":"e_1_2_10_21_1","unstructured":"Carlella M.A.Botulinum toxoids. In: Botulism Proc. a Symp. (Lewis KH) 113\u2013130 (Government Printing Office: PHS Publication Washington DC 1964)."},{"key":"e_1_2_10_22_1","unstructured":"FDA BAT(Botulism Antitoxin Heptavalent (A B C D E F G) \u2010 (Equine). (2018) <https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/approved\u2010blood\u2010products\/bat\u2010botulism\u2010antitoxin\u2010heptavalent\u2010b\u2010c\u2010d\u2010e\u2010f\u2010g\u2010equine>."},{"key":"e_1_2_10_23_1","volume-title":"Pharmacokinetic and Pharmacodynamic Data Analysis \u2013 Concepts and Applications","author":"Gabrielsson J.","year":"2016"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03297.x"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12015"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/150.3.407"},{"key":"e_1_2_10_27_1","first-page":"473","article-title":"Human botulism caused by Clostridium botulinum type E: the Birmingham outbreak","volume":"48","author":"Ball A.","year":"1979","journal-title":"Q. J. Med."},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.20.2476"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.104661"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018943613122"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2219-y"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-013-9332-2"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12706"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/antib10030035"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.708"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009337134"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2620","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.2620","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.2620","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:27:45Z","timestamp":1699363665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.2620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/cpt.2620"],"URL":"https:\/\/doi.org\/10.1002\/cpt.2620","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,16]]},"assertion":[{"value":"2021-11-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}